Company Overview and News

 
KLCI up 0.26% in line with regional gains

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI rose 0.26% at the midday break today and stayed firmly above the 1,800-point level, tracking gains at regional markets.
HLFBF 7251 BATS 4162 2089 7077 5029 5347 1201 5225 TNABY 2836 IHHHF PNAGF 5183 PECGF UPBMF 1082 7765 6033 2593 PNADF TNABF Q0F 3719

 
KLCI holds position above 1,800 level, gains seen capped

2018-08-09 theedgemarkets
KUALA LUMPUR (Aug 9): The FBM KLCI managed to hold its position above the 1,800-point level at mid-morning today, but gains were seen capped in line with the subdued regional markets.
HLFBF 7172 5198 1082 7412 7043 7077 2852 5029 5347 5225 1201 3301 TNABY 5819 2836 TNABF Q0F IHHHF 3719

 
Eye On Stock: GSB Group

2018-08-03 thestar.com.my
GSB Group Bhd (code: 7077) may be showing some indecision but it is holding on to positive momentum, suggesting that it may be making further challenge to the resistance in the immediate term.
7077

 
Stock With Momentum: GSB Group

2018-08-03 theedgemarkets
TRADING of shares in GSB Group Bhd (fundamental: 0.15/3, valuation: 0/3) triggered our momentum algorithm yesterday as its share price rose 9.3% to an intraday high of 23.5 sen before closing unchanged at 21.5 sen with 38.3 million shares changing hands. This was significantly higher than its 200-day average volume of 4.41 million shares.
7077

17
KLCI falls 0.47% in subdued start to 2H2018

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): The FBM KLCI fell 0.47% at midday break today, as latest data showed business conditions across Malaysia’s manufacturing sector deteriorating, albeit at a slower pace in June.
HLFBF PBLOF 7113 7036 TPGVF 1295 7077 9334 DKSHY 5347 3301 8613 TNABY 5908 HRGHY SPMXF 1082 5681 5168 1481 TGLVY 5139 4588 SPMXY 0900 5819 TNABF DKSHF

18
KLCI remains in the red in slow start to 2H2018

2018-07-02 theedgemarkets
KUALA LUMPUR (July 2): The FBM KLCI remained subdued at mid-morning today after data showed business conditions across Malaysia’s manufacturing sector deteriorating albeit at a slower pace in June.
7052 PBLOF BATS 4162 1295 3794 2089 7077 5199 DKSHY KLKBY 3867 7206 HIPEF 5908 SPMXF UPBMF 8133 1481 5139 2445 4588 SPMXY 0026 0900 5819 DKSHF

 
Stock With Momentum: GSB Group Bhd

2018-06-22 theedgemarkets
GSB Group Bhd (-ve) SHARES in GSB Group Bhd (fundamental: 0.15/3, valuation: 0/3) triggered our proprietary momentum algorithm for the 10th time this year. The stock closed 0.5 sen or 2.17% higher to 23.5 sen with a market capitalisation of RM124.50 million. A total of 47.39 million shares changed hands, exceeding the counter’s 200-day average volume of 2.94 million shares.
7077

 
GSB Group upside may be capped, says PublicInvest Research

2018-06-22 theedgemarkets
In a trading ideas note today, the research house however said the price movement is currently showing sign of being overbought and a cool down might be needed.
7077

23
KLCI falls 1.08% as telcos, banks drag

2018-06-21 theedgemarkets
KUALA LUMPUR (June 21): The FBM KLCI fell 1.08% at the midday break today, dragged by losses at index-linked telecommunications and banking stocks.
HLFBF PBLOF 4065 1082 BATS 4162 2291 AMMHF 7765 1295 7077 KLKBY 2445 1015 4863 5347 TNABY 6888 5819 AXXTF MYTEF TNABF GEBHF 3719

17
KLCI remains lacklustre, tracks subdued region

2018-06-21 theedgemarkets
KUALA LUMPUR (June 21): The FBM KLCI remained lacklustre at mid-morning today, tracking the subdued regional markets.
UPBMF 4065 5681 BATS 4162 2291 2089 7077 6033 0036 PNADF 4456 4863 5258 5819 MYTEF PNAGF

17
KLCI pares gains as regional sentiment turns tepid

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI pared its gains substantially at the midday break today, tracking its regional peers as China's stock markets fell.
HLFBF APEXF PBLOF 7090 UPBMF 1082 5681 BATS 4162 1295 2089 7077 5014 9598 KLKBY 2445 3301 2216 5819 MYPRY

18
KLCI rises 0.68%, tracks gains at regional markets

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI rose 0.68% at mid-morning today, tracking the rebound at most regional markets.
APEXF PBLOF 7090 UPBMF 4065 8621 7113 TPGVF 6521 7087 1295 2089 7077 5014 TGLVY KLKBY 2445 2216 5819 MYPRY 3719

 
New chairman gives GSB’s shares a boost

2018-06-20 thestar.com.my
KUALA LUMPUR: Shares in GSB Group Bhd edged almost 11% higher in early trade following the announcement that Datin Toh Siew Chuon would take over as its executive chairman.
7077

2
Trading ideas: Top Glove, Gabungan AQRS, GSB Group, Kerjaya Prospek, AirAsia

2018-06-20 thestar.com.my
KUALA LUMPUR: Top Glove Corp Bhd , Gabungan AQRS Bhd , GSB Group Bhd AirAsia Group Bhd are among the stocks to watch, according to JF Apex Research.
TGLVY 5226 7113 TPGVF 7077

2
KLCI could slip below 1,700-level as trade war fears escalate

2018-06-20 theedgemarkets
KUALA LUMPUR (June 20): The FBM KLCI could slip below the 1,700-point level today, as local investor sentiment could take a beating in line with the overnight fall at most global markets.
TGLVY 9385 5226 7113 7168 TPGVF 7077

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...